FibroScan在合并肝细胞脂肪变性的慢性乙型肝炎患者肝纤维化诊断中的作用

刘柯慧; 谢敬东; 阮隽; 余敏杰; 林兰意; 安宝燕; 周惠娟; 谢青; 王晖

doi:10.3969/j.issn.1001-5256.2014.02.014

FibroScan在合并肝细胞脂肪变性的慢性乙型肝炎患者肝纤维化诊断中的作用

DOI: 10.3969/j.issn.1001-5256.2014.02.014

上海交通大学医学院附属瑞金医院感染科

基金项目:

国家自然科学基金(81070334)；十二五国家科技重大专项资助项目(2012ZX10005004-002)；中国肝炎防治基金会王宝恩肝纤维化研究基金；上海市公共卫生人才培养计划(GWDTR201202)；

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 3382
- HTML全文浏览量: 5
- PDF下载量: 649
- 被引次数: 0
出版历程
- 出版日期: 2014-02-20

Value of FibroScan in assessment of liver fibrosis in chronic hepatitis B patients with hepatocyte steatosis

Research funding:

摘要

摘要:
目的探讨肝脏瞬时弹性成像（FibroScan）在诊断合并肝细胞脂肪变性的慢性乙型肝炎（CHB）患者肝纤维化中的价值。方法选择2009年1月-2011年12月本院行经皮肝穿刺活组织检查的CHB患者418例,分为无肝细胞脂肪变性组（207例）和合并肝细胞脂肪变性组（211例）,2组同期行FibroScan等检测,将FibroScan测定值与Ishak评分进行比对,组间比较采用成组t检验、Kruskal-Wallis H检验和Nemenyi检验。计数资料组间比较采用卡方检验。双变量相关性分析采用Spearman等级相关系数法。使用逐步回归的统计学方法从可能影响FibroScan检测结果的多种因素中筛选出有实际意义的影响因素。结果分别对2组内相同肝脏纤维化分期患者的肝硬度值（Stiffness值）进行比较,差异均无统计学意义（P>0.05）,且Stiffness值均与肝纤维化分期呈显著正相关,无肝细胞脂肪变性组,rs=0.650 35,P<0.000 1;合并肝细胞脂肪变性组,rs=0.637 93,P<0.000 1。逐步回归统计分析显示,无脂肪变性CHB组,AST、ALT...
- 肝炎,乙型,慢性 /
- 脂肪肝 /
- 肝硬化 /
- 弹性成像技术
Abstract:
Objective To evaluate the value of FibroScan in assessing liver fibrosis in chronic hepatitis B ( CHB) patients with hepatocyte steatosis. Methods Four hundred and eighteen CHB patients who had undergone liver biopsy in Shanghai Ruijin Hospital from January 2009 to December 2011 were enrolled in this study. These patients were divided into hepatocyte steatosis group ( n = 211) and non- hepatocyte steatosis group ( n =207) . FibroScan was performed in both groups on the same day. Comparisons of liver stiffness measurement ( LSM) and liver fibrosis stage determined by FibroScan and Ishak scoring system were made. Comparisons between groups were made by independent- samples t test, Kruskal- Wallis H test, and Nemenyi test. Comparison of categorical data was made by chi- square analysis. Bivariate correlation analysis was performed using the Spearman Rank Correlation coefficient. The influential factors for LSM were determined by stepwise regression analysis. Results There was no significant difference in LSM between the patients of the same liver fibrosis stage in the two groups ( P > 0. 05) , and LSM had a significant positive correlation with liver fibrosis stage in the non- hepatocyte steatosis group ( rs= 0. 650 35, P < 0. 000 1) and hepatocyte steatosis group ( rs= 0. 637 93, P < 0. 000 1) . The stepwise regression analysis showed that aspartate aminotransferase ( AST) , alanine aminotransferase, albumin ( Alb) , total bilirubin, and platelet ( PLT) were significant influential factors for LSM in the non- hepatocyte steatosis group and that PLT, AST, age, Alb, and body mass index were significant influential factors for LSM in the hepatocyte steatosis group. Conclusion FibroScan can be used as a useful tool for assessing liver fibrosis in CHB patients with hepatocyte steatosis.
- hepatitis B, chronic /
- fatty liver /
- liver cirrhosis /
- elasticity imaging techniques

HTML全文

参考文献(20)

[1]SANDRIN L, FOURQUET B, HASQUENOPH JM, et al.Transient elastography:a new noninvasive method for assessment of hepatic fibrosis[J].Ultrasound Med Biol, 2003, 29 (12) :1705-1713.

[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese MedicalAssociation.The guideline of prevention and treatment for Chinese hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[3]ISHAK K, BAPTISTA A, BIANCHI L, et al.Histological grading and staging of chronic hepatitis[J].J Hepatol, 1995, 22 (6) :696-699.

[4]ROCKEY DC.Antifibrotic therapy in chronic liver disease[J].Clin Gastroenterol Hepatol, 2005, 3 (2) :95-107.

[5]YAO GB.Clinical hepatology[M].Second Edition.Shanghai:Shanghai Science and Technology Press, 2011:109-110, 388-396. (in Chinese) 姚光弼.临床肝脏病学[M].2版.上海:上海科学技术出版社, 2011:109-110, 388-396.

[6]SHI JP, FAN JG.Advances in researches on relationship of steatosis with hepatitis B virus infection[J].Int J Dig Dis, 2008, 28 (2) :100-105. (in Chinese) 施军平, 范建高.肝细胞脂肪变与乙型肝炎相关性研究进展[J].国际消化病杂志, 2008, 28 (2) :100-105.

[7]YANG AT, WANG BE, YOU H.New evidence of FibroScan's clinical value for assessingfibrosis, screening liver disease, monitoring chronic liver disease progression, and predicting outcome[J].J Clin Hepatol, 2012, 28 (9) :644-646. (in Chinese) 杨爱婷, 王宝恩, 尤红.FibroScan评估纤维化、筛查肝脏疾病、监测慢性肝病进展及预测预后的新证据[J].临床肝胆病杂志, 2012, 28 (9) :644-646.

[8]ARENA U, VIZZUTTI F, ABRALDES JG, et al.Reliability of transient elastography for the diagnosisof advanced fibrosis on chronic hepatitis C[J].Gut, 2008, 57 (9) :1288-1293.

[9]GANNE-CARRIN, ZIOL M, de LEDINGHEN V, et al.Accuracy of liver stiffness measurement forthe diagnosis of cirrhosis in patients with chronic liver disease[J].Hepatology, 2006, 44 (6) :1511-1517.

[10]WANG VW, VERGNIOL J, WONG GL, et al.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (2) :454-462.

[11]NAHON P, KETTANEH A, TENGHER-BARNA I, et al.Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease[J].J Hepatol, 2008, 49 (6) :1062-1068.

[12]SPOREA I, JURCHIS A, SIRLI R, et al.Can transient elastography be a reliable method forassessing liver fibrosis in non alcoholic steatohepatitis (NASH) ?[J].Med Ultrason, 2013, 15 (2) :106-110.

[13]KIM BK, FUNG J, YUEN MF, et al.Clinical application of liver stiffness measurement usingtransient elastography in chronic liver disease from longitudinal perspectives[J].World J Gastroenterol, 2013, 19 (12) :1890-1900.

[14]FRAQUELLI M, POZZI R.The accuracy of noninvasive methods in the prediction of clinically relevant outcomes in patients with chronic liver disease[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (6) :679-682.

[15]MARCELLIN P, ZIOL M, BEDOSSA P, et al.Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B[J].Liver Int, 2009, 29 (2) :242-247.

[16]WEN X, WANG XM, WANG BY.Recent advances in the use of FibroScan for diagnosis of liverfibrosis[J].World Chin J Dig, 2009, 17 (31) :3223-3228. (in Chinese) 温欣, 王学梅, 王炳元.FibroScan对肝纤维化诊断价值的研究进展[J].世界华人消化杂志, 2009, 17 (31) :3223-3228.

[17]TAN YJ, JI D, NIU XX, et al.Frequency and determinants of liver stiffness measurement failure[J].J Med Res, 2012, 41 (11) :30-33. (in Chinese) 谭有娟, 纪冬, 牛小霞, 等.瞬时弹性成像检测肝硬度失败的因素及分析[J].医学研究杂志, 2012, 41 (11) :30-33.

[18]FRAQUELLI M, RIGAMONTI C, CASAZZA G, et al.Etiologyrelated determinants of liver stiffnessvalues in chronic viral hepatitis B or C[J].J Hepatol, 2011, 54 (4) :621-628.

[19]ZIOL M, HANDRA-LUCA A, KETTANEH A, et al.Noninvasive assessment of liver fibrosis by measurement of stiffness in patient with chronic hepatitis C[J].Hepatology, 2005, 41 (1) :48-54.

[20]CHAN HL, WONG GL, CHOI PC, et al.Alanine aminotransferase-based algorithms of liverstiffness measurement by transient elastography (FibroScan) for liver fibrosis in chronichepatitis B[J].J Viral Hepat, 2009, 16 (1) :36-44.

施引文献

资源附件(0)

访问统计